0

Salirasib

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP162520005
CAS162520-00-5
Structure
MDL NumberMFCD00467723
Molecular Weight358.54
InChI KeyWUILNKCFCLNXOK-CFBAGHHKSA-N
Description≥98% (HPLC)
SolubilityDMSO: 20 mg/mL, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size10MG, 50MG
Storage Conditions−20°C
1

An Early Clinical Trial of Salirasib, an Oral RAS Inhibitor, in Japanese Patients With relapsed/refractory Solid Tumors

Junji Furuse, Takayasu Kurata, Naohiro Okano, Yasuhito Fujisaka, Daisuke Naruge, Toshio Shimizu, Hiroshi Kitamura, Tsutomu Iwasa, Fumio Nagashima, Kazuhiko Nakagawa

Cancer Chemother Pharmacol. 2018 Sep;82(3):511-519.

PMID: 29992354

1

HRAS as a Potential Therapeutic Target of Salirasib RAS Inhibitor in Bladder Cancer

Satoshi Sugita, Hideki Enokida, Hirofumi Yoshino, Kazutaka Miyamoto, Masaya Yonemori, Takashi Sakaguchi, Yoichi Osako, Masayuki Nakagawa

Int J Oncol. 2018 Aug;53(2):725-736.

PMID: 29901113

1

Is Ras a Potential Target in Treatment Against Cutaneous Squamous Cell Carcinoma?

Li Li, Min Li, Song Xu, Wenbo Bu, Mengli Zhang, Heng Gu, Xu Chen

J Cancer. 2018 Sep 8;9(18):3373-3381.

PMID: 30271499

1

Repositioning Salirasib as a New Antimalarial Agent

Exequiel O J Porta, Ignasi Bofill Verdaguer, Consuelo Perez, Claudia Banchio, Mauro Ferreira de Azevedo, Alejandro M Katzin, Guillermo R Labadie

Medchemcomm. 2019 Jun 21;10(9):1599-1605.

PMID: 31803400

1

Salirasib in the Treatment of Pancreatic Cancer

Ernesto Bustinza-Linares, Razelle Kurzrock, Apostolia-Maria Tsimberidou

Future Oncol. 2010 Jun;6(6):885-91.

PMID: 20528225

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode